Note: results can be filtered by year and/or keyword. To filter on year, select the appropriate year from the drop down menu. To filter on keyword, enter relevant term into open box, select appropriate keyword, and click "filter".
Reports & Briefings
2nd Edition January 2015 Immunisation is one of the most efficient ways to reduce child mortality. Yet, every year 1 out of every 5 children (under the age of 1 year) is not fully vaccinated, putting them at risk of dying of preventable diseases such as measles, pneumonia or diarrhoea.
Last updated 20 January 2015
A survey of TB diagnostic and treatment practices in eight countries
Last updated 20 October 2014
This 17th edition of Untangling the Web of Antiretroviral Price Reductions is a departure from recent previous years. For this edition, the methods of collecting information on the sources and prices of antiretrovirals (ARVs) remain the same, but information is presented in a new, shorter format focusing on a few key drugs as well as future regimens, along with an analysis of the current opportunities, challenges and threats faced in keeping the price of ARVs down. DOWNLOAD THE BRIEFING DOCUMENT
Opportunities to Revolutionise Care in Developing Countries This report provides an overview on the current state of play and a framework for action with regards to hepatitis C diagnostics and treatment in resource-poor settings.
Last updated 8 April 2014
Lack of information on both the price and the different product characteristics of vaccines has been limiting countries’ ability to operate affordable and effective immunisation programmes.
Last updated 16 January 2014
This report focuses on just some of the many factors that hamper the scaling up of DR-TB treatment – the limited availability and high cost of quality-assured medicines for resistant strains of the disease, owing to an insecure market and insufficient demand; and the research questions that remain unsolved with existing medicines.
Last updated 26 October 2013
With nearly 13 million people on antiretroviral therapy world-wide, which is less than half the number of people eligible to receive it, the price of antiretroviral (ARV) drugs to put people on treatment remains a critical one.
Last updated 2 July 2013
Last updated 2 July 2013
Buruli ulcer disease is a serious necrotizing skin infection caused by the environmental pathogen Mycobacterium ulcerans and represents the third most common mycobacterial infection worldwide after tuberculosis and leprosy. This disease, if left untreated, can lead to disfiguring and disabling lesions, particularly affecting young populations in resource-poor settings.
Last updated 26 March 2013
Over the past half century, there have been unprecedented improvements in health outcomes, spurred in part by unparalleled scientific progress in the pharmaceutical sector. Yet access to the benefits of medical progress and scientific advancement has not been equitably shared and many innovation gaps remain. Three fundamental problems persist: 1. Global health needs are not in the driver's seat
Last updated 12 December 2012